Jubilant Life Sciences' shares injected with vitality

Jubilant Life Sciences, the BSE 200 stock is no mood to compromise. The scrip of the company on Aug 30 has rallied over 5 per cent on an intraday basis. This month was quite favourable for the company, as in the entire month company managed to grab the investors’ attention. For instance, on Aug 24 and 25, company received ANDA approval for Felodipine ER and Telmisartan tablets. The employee stock option plan of the company which was given by the company to its eligible employees in the year 2005 and 2011 was also exercised by the option holders on Aug 29. On the other hand, early this month on Aug 9, company posted its financial results. In Q1FY17, company has posted a net profit of Rs 162 crores, which increased by 22 per cent YoY.

Shares of the company as at 11.04 am on Aug 30 are trading at Rs 535.55, up by 5.43 per cent. In the last, 1 month, shares have taken the aerial route by surging more than 64 per cent. Fifty-two-weeks' High/Low of the company stands at Rs 546.70/261.Jubilant Life Sciences Limited, is an integrated global pharmaceutical and life sciences company, and it also provides services in contract manufacturing of sterile injectable and drug discovery solutions.